Skip to content

Board of Directors

Jay led Illumina as CEO from 1999 until 2016 and now serves as Executive Chairman of the Board of Directors. During his tenure as CEO, he took the company from $1.3 million in sales in 2000 to $2.2 billion in 2015, representing a compound annual growth rate of 64 percent. He oversaw the company’s expansion from microarrays into next-generation sequencing with the acquisition of Solexa in 2006, and from research into clinical and applied markets. Under his leadership, Illumina was named multiple times to the Deloitte & Touche Fast 50 and Fast 500 lists, as well as to the Forbes 25 Fastest-Growing Tech Companies (2007, 2009 and 2010), the Fortune 100 Fastest-Growing Companies (2010 and 2011) lists, and recognition by MIT Technology Review as the World’s Smartest Company in 2014.

Jay chairs the Board of Directors for Illumina and its subsidiary, Helix. In addition to his work at Illumina, he serves on the Boards of Directors at Coherent, Denali, Dodo Omnidata and on the Board of Trustees for The Salk Institute and is an Advisory Board member for UC San Diego’s Moores Cancer Center.

Previously, Jay served as President and Chief Executive Officer of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare. As a co-founder and member of the board of directors for Molecular Dynamics he led the company to its initial public offering in 1993. While there, he also helped Molecular Dynamics develop and launch over 15 major instrumentation systems, including the first capillary-based DNA sequencer. Prior to joining Molecular Dynamics, Jay was Vice President of Engineering and Strategic Planning for Plexus Computers, Executive Vice President for Manning Technologies and held various positions at Spectra Physics.

Jay received a B.A. in economics from Claremont McKenna College and a B.S. and M.S. (summa cum laude) in industrial engineering from Stanford University.

Francis deSouza was appointed President & CEO of Illumina in 2016 and is responsible for directing all aspects of company strategy, planning, and operations. He initially joined the company as President in 2013, and led Illumina’s business units and core functions responsible for envisioning, developing and producing the company’s products.

Previously, deSouza served as President of Products and Services at Symantec Corporation, where he was responsible for driving the vision for the company’s market-leading portfolio and served in a variety of executive roles. He joined Symantec through the acquisition of IMlogic, where he was co-founder and CEO.

Prior to joining IMlogic, deSouza was co-founder and CEO of Flash Communications, a provider of corporate instant messaging that was acquired by Microsoft. Following the acquisition, he joined Microsoft and led the team responsible for the development of the company’s enterprise real-time collaboration offerings. Currently, he is a member of the board of directors for The Walt Disney Company.

Francis deSouza received a B.S. and M.S. in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.

Dr. Arnold has been a director since 2016. Dr. Arnold manages a research group at the California Institute of Technology and is the Dick and Barbara Dickinson Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology and Director of the Donna and Benjamin M. Rosen Bioengineering Center. She joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor, and Director. Dr. Arnold’s laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals, and medicine. She is the recipient of numerous honors, including the Millennium Technology Price, induction into the National Inventors Hall of Fame, Fellow of the National Academy of Inventors, the ENI Prize in Renewable and Nonconventional Energy, the U.S. National Medal of Technology and Innovation, and the Charles Stark Draper Prize of the U.S. National Academy of Engineering. Dr. Arnold is an elected member of all three U.S. National Academies of Science, Medicine, and Engineering, as well as the American Academy of Arts and Sciences. Dr. Arnold serves as a director of Provivi, Inc., a privately-held biopesticide company.

Dr. Arnold received a B.S. in mechanical and aerospace engineering from Princeton University and a Ph.D. in chemical engineering from the University of California, Berkeley.

Ms. Dorsa has been a director since January 2017. Ms. Dorsa served as Executive Vice President and Chief Financial Officer of Public Service Enterprise Group Incorporated, a NYSE-listed diversified energy company, from April 2009 until her retirement in October 2015, and served on its Board of Directors from 2003 to April 2009. From February 2008 to April 2009, she served as Senior Vice President, Global Human Health, Strategy and Integration at Merck & Co., Inc., a NYSE-listed pharmaceutical company. From November 2007 to January 2008, Ms. Dorsa served as Senior Vice President and Chief Financial Officer of Gilead Sciences, Inc., a NASDAQ-listed life sciences company. From February 2007 to November 2007, she served as Senior Vice President and Chief Financial Officer of Avaya, Inc., a NYSE-listed telecommunications company. From 1987 to January 2007, Ms. Dorsa held various financial and operational positions at Merck & Co., Inc., including Vice President and Treasurer, Executive Director of U.S. Customer Marketing, and Executive Director of U.S. Pricing and Strategic Planning.

Ms. Dorsa also serves on the Board of Directors of Biogen Inc. and Intellia Therapeutics, Inc., and is on the Board of Trustees of the Goldman Sachs ETF Trust, the Goldman Sachs MLP and Energy Renaissance Fund and the Goldman Sachs MLP Income Opportunities Fund, investment funds within the Goldman Sachs fund complex.

Ms. Dorsa received her M.B.A. from Columbia University and a B.A. from Colgate University.

Ms. Eastham has been a director since July 2004. She has over 30 years of experience in financial and operations management, primarily in life sciences companies. Ms. Eastham serves as a director for 4 public biotechnology companies, Illumina, Inc., Geron Corporation, Veracyte, Inc. and MorphoSys AG (based in Munich, Germany). Her former directorships include Amylin Pharmaceuticals, Genoptix, Tercica,Trius Therapeutics, SGX, Salmedix, Molecular Probes and Cyntellect. Ms. Eastham’s career includes her service as Executive Vice President and Chief Operating Officer and Trustee of the Burnham Institute for Medical Research. She also served as Senior Vice President, Finance, Chief Financial Officer, and Secretary of Diversa Corporation. She held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics.

Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.

Ms. Eastham is the recipient of several prestigious awards, including the 2004 Women Who Mean Business Award, the UCSD Athena 2007 Technology Pinnacle Award and the Corporate Directors Forum 2007 Director of the Year Award in Corporate Governance in addition to the 2014 Lifetime Achievement Award. Ms. Eastham is the author of award-winning book, Cook the Part: Delicious, Interactive and Fun Team Cooking (Crosswalk Press October 2011). This book combines her leadership experience with her passion for cooking.

Dr. Epstein has been a director since November 2012. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector. From 2010 to 2012, Dr. Epstein was Chief R&D Officer and President of Medco-UBC, a 2,400 person global research organization focused on conducting personalized medicine, health economics, drug safety, outcomes, and comparative effectiveness research on behalf of the biopharmaceutical, medical device, and diagnostics industries. Prior to this role, Dr. Epstein was Medco’s Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is also the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the boards of directors of the Drug Information Association (DIA) and the International Society of Quality of Life. Dr. Epstein serves on the Board of Directors of Fate Therapeutics, Inc. and Veracyte, Inc. Dr. Epstein also serves as a director of the following privately-held companies: Intellos LLC, a diagnostics company; and Proteus Digital Health, a healthcare technology company. Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA (The Journal of the American Medical Association).

Dr. Epstein received his M.D. and B.S. in biomedical science from the University of Michigan and an M.S. in preventative medicine from the University of Maryland.

Gary S. Guthart, Ph.D. has been director since December 2017. Dr. Guthart is currently President and Chief Executive Officer of Intuitive Surgical, a global leader in the field of robotic-assisted minimally invasive surgery. He joined Intuitive Surgical in April 1996 and has served as the Chief Executive Officer since January 2010. In July 2007, he was promoted to President, having assumed the role of Chief Operating Officer in February 2006. Prior to joining Intuitive Surgical, Dr. Guthart was part of the core team developing foundation technology for computer enhanced-surgery at SRI International (formerly Stanford Research Institute). Dr. Guthart served as a member of the Board of Directors of Affymetrix, Inc. from May 2009 until its acquisition by Thermo Fisher Scientific Inc. in March 2016.

Dr. Guthart received a B.S. in Engineering from the University of California, Berkeley and an M.S. and a Ph.D. in Engineering Science from the California Institute of Technology.

Mr. Schiller has been a director since July 2016. Mr. Schiller rejoined Apple Inc. in April 1997 and assumed his current position as Senior Vice President, Worldwide Marketing in February 2002 and is a member of Apple’s executive team responsible for the company’s product marketing, developer relations, business marketing, education marketing, international marketing, and App Store programs. He has helped Apple create and market some of the best-selling products in the world including the Mac, iPod, iTunes, iPhone, the App Store, Apple TV, and the Apple Watch. Prior to rejoining Apple, Mr. Schiller was Vice President of Product Marketing at Macromedia, Inc. from 1995 to 1997 and Director of Product Marketing at FirePower Systems, Inc. from 1993 to 1995. Prior to that, Mr. Schiller spent six years at Apple in various marketing positions.

Mr. Schiller received a B.S. in biology from Boston College.

John W. Thompson has been a director since 2017. He brings executive leadership experience having served as chief executive officer roles at Virtual Instruments and Symantec as well as 28 years of prior leadership experience at IBM where he held senior roles in sales, marketing, software development and as general manager of IBM Americas. He is chairman of the board at Microsoft and has served on the corporate boards of Symantec, NIPSCO (Northern Indiana Public Service Company), Fortune Brands, Seagate Technologies, and United Parcel Service (UPS). Mr. Thompson is a member of the board of trustees for the Wetlands America Trust and formerly a member of the national board of Teach for America. In addition, he has served on several government commissions including the Financial Crisis Inquiry Commission, the National Infrastructure Advisory Council, and the Silicon Valley Blue Ribbon Task Force on Aviation Security and Technology.

He received his B.A. in business administration from Florida A&M University and M.S. in management science from MIT’s Sloan School of Management.

Committee Composition

  Audit Committee Compensation Committee Nominating and Corporate
Governance Committee
Frances Arnold, PhD      
Caroline Dorsa      
Karin Eastham      
Robert S. Epstein, MD      
Philip Schiller      
Gary S. Guthart, PhD      
John W. Thompson      
Committee Charter PDF Download PDF Download PDF Download PDF
  • = Member
  • = Chairperson
  • = Financial Expert